/
Other
Phase II
34
Pipeline Programs↗
23
Active Trials↗
66
Companies Involved↗
Phase II is a moderately active landscape with 34 programs across 66 companies. The most active players are AstraZeneca, Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd., LaNova Medicines Limited. 4 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 229
Phase 34
Approved
No programs
Analysis
Modality Breakdown
76%
Small molecule
25 of 33 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 33 classified programs, each share of the total. Modality classified for 100% of 34 pipeline programs.
Analysis
Trial Status
219
clinical trials
Completed140 · 64%
Terminated26 · 12%
Unknown status25 · 11%
Recruiting12 · 5%
Active, not recruiting7 · 3%
Not yet recruiting4 · 2%
Other5 · 2%
Clinical Trials
Trial Activity
219 trials
Phase II Trial of Lung Chemoemobolization
Recruiting·—·Phase 2·NCT05672108·30 enrolled
A Phase II Study of CRT Combined With QL1706 in ESCC Patients
Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT05490719·39 enrolled
HIV-1 Infected Patients, Phase II Trial, Dual Combination Doravirine/Raltegravir Open Label
Recruiting·CCentre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida·Phase 2·NCT04513626·150 enrolled
Phase II Study of FCN-159 in NF2 Nerve Sheath Tumors
Recruiting·—·Phase 2·NCT06553365·30 enrolled
SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST
Active, not recruiting·SSarcoma Alliance for Research through Collaboration·Phase 2·NCT06208748·40 enrolled
Page 1 of 15
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)